Last updated: 2026-09-10 12:16:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
OmniAb, Inc. (OABI) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $3,96, with a market capitalization of $616,46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,30 to $5,43. This page covers its latest market performance, valuation, price trends and company information.
$616,46M | |
$3,98 | |
$6,72 | |
$1,22 | |
$4,01 | |
51,00 | |
1,24M | |
-- | |
$5,43 | |
$1,30 | |
-- | |
-- |
OmniAb, Inc. (OABI) is trading at $3,96 in pre-market trading as of 2026-09-10 11:56:00, down 1,34% ($0,05) from the previous close of $4,02
Pre-market trading shows how investors are pricing OABI before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, OmniAb, Inc. (OABI) moved from $4,38 to $3,96, representing a decline of 9,57% ($0,42).
The stock traded between $3,96 and $5,43 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,94 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 64,4%
OABI is currently trading at $3,96, placing it 64,4% of the way from its 52-week low of $1,30 to its 52-week high of $5,43. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 89 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OmniAb, Inc. (OABI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.